TG01

BIOLOGICAL3 trials

Sponsors

Tragara Pharmaceuticals, Inc., Targovax ASA, Oslo University Hospital

Conditions

Multiple MyelomaNon-small Cell Lung CancerPancreatic Cancer, ResectedSmoldering Multiple Myeloma

Phase 1

Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients

CompletedNCT00569114

Tragara Pharmaceuticals, Inc.Non-small Cell Lung Cancer

Start: 2007-10-31End: 2009-11-30Target: 45Updated: 2010-03-17

Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

CompletedNCT02261714

Targovax ASAPancreatic Cancer, Resected

Start: 2012-12-31End: 2019-05-31Updated: 2020-05-14

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

RecruitingNCT05841550

Oslo University HospitalMultiple Myeloma, Smoldering Multiple Myeloma

Start: 2023-05-19End: 2035-05-19Target: 20Updated: 2025-08-05

Related Papers

Vaccinating Against Mutated RAS in Multiple Myeloma: The Phase I/II TG01/QS-21 Study

Blood2024-11-05

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

British Journal of Cancer2020-02-1763 citations

A phase I/II trial of TG01/GM-CSF and gemcitabine as adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas.

Journal of Clinical Oncology2017-05-2012 citations

A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma.

Journal of Clinical Oncology2015-05-203 citations